Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Northwestern University
With
OSI Pharmaceuticals
Psoriasis vulgaris is a disease that affects 25 million people in North America and Europe. It often presents in late adolescence and usually persists for life. Current therapies target specific immune molecules that are implicated in the cause of this disease. For example, biologic agents that are used in severe psoriasis are aimed at inflammatory mediators. These therapies have been proven to be effective but also have their limitations.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of moderate to severe psoriasis
Must have documented moderate to severe psoriasis by the Physician's Global Assessment (PGA) and the Psoriasis Area Severity Index (PASI)
Must be able to swallow tablets
Must be able to provide written informed consent
Subjects with reproductive potential (menopausal for less than 1 year and not surgically sterilized) must practice effective contraceptive measures throughout the study and thirty days after discontinuation of study drug. Women of childbearing potential must provide negative pregnancy test (serum or urine) within 14 days prior to randomization.
You may not be if
Use of concurrent agents/therapies for psoriasis
Bilirubin \> 3 X ≥ ULN or moderate to severe hepatic impairment
Pregnant or breast-feeding females
Subjects currently receiving other anticancer treatments
Subjects currently receiving other biologic treatments
Subjects currently receiving blood thinners (warfarin or heparin)
Subjects who currently smoke
Subjects with other skin disease which in the opinion of the investigator, would inhibit the ability to use the PGA and PASI evaluation methods
